Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer

被引：0
|
作者：
Amadori, D.
Gasparini, G.
Ardizzoni, A.
Comella, G.
Saracchini, S.
Barone, C.
Bordonaro, R.
Djazouli, K.
Barbalo, A.
机构：
[1] Ist Sci Romagnolo Studio & Lacura Tumori, Meldola, Forli Cesena, Italy
[2] Azienda Complesso Osped S Filippo Neri, Rome, Italy
[3] AO Univ Parma, Parma, Italy
[4] Fondaz G Pascale, Naples, Italy
[5] AO Santa Maria Angeli, Pordenone, Italy
[6] Policlin Univ A Gemelli, Rome, Italy
[7] Azienda Garibaldi, Catania, Italy
[8] Cephalon Europe, Paris, France
[9] Cephalon Srl, Rome, Italy
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：247S / 247S
页数：1
相关论文
共 50 条
  • [21] Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer
    Alexopoulos, A
    Karamouzis, MV
    Stavrinides, H
    Ardavanis, A
    Kandilis, K
    Stavrakakis, J
    Georganta, C
    Rigatos, G
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 891 - 895
  • [22] Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
    Infante, Jeffrey R.
    Yardley, Denise A.
    Burris, Howard A., III
    Greco, F. Anthony
    Farley, Cindy P.
    Webb, Charles
    Spigel, David R.
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (01) : 23 - 28
  • [23] Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
    Venturini, M
    Bighin, C
    Monfardini, S
    Cappuzzo, F
    Olmeo, N
    Durando, A
    Puglisi, F
    Nicoletto, O
    Lambiase, A
    Del Mastro, L
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 95 (01) : 45 - 53
  • [24] Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
    M. Venturini
    C. Bighin
    S. Monfardini
    F. Cappuzzo
    N. Olmeo
    A. Durando
    F. Puglisi
    O. Nicoletto
    A. Lambiase
    L. Del Mastro
    Breast Cancer Research and Treatment, 2006, 95 : 45 - 53
  • [25] Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Dias, Zetina L.
    Gaui, M.
    Otero Reyes, D.
    Jassem, J.
    Button, P.
    Bell, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [26] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
    Ghosn, M.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    El-Mouhebb, M.
    Mourad, C.
    Farhat, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S183
  • [27] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer
    Farhat, F.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    Ghosn, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S281
  • [28] ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER
    Farhat, Fadi
    Kattan, Joseph
    Ghosn, Marwan
    BREAST, 2015, 24 : S42 - S43
  • [29] A Phase II Study of Lipoplatin (Liposomal Cisplatin)/Vinorelbine Combination in HER-2/neu-Negative Metastatic Breast Cancer
    Farhat, Fadi S.
    Temraz, Sally
    Kattan, Joseph
    Ibrahim, Khaled
    Bitar, Nizar
    Haddad, Nadine
    Jalloul, Rahif
    Hatoum, Hassan A.
    Nsouli, Ghazi
    Shamseddine, Ali I.
    CLINICAL BREAST CANCER, 2011, 11 (06) : 384 - 389
  • [30] Phase I study of liposomal doxorubicin (Caelix) and docetaxel as first line treatment in patients with metastatic breast cancer.
    Morabito, A
    Fanelli, M
    Gilberti, S
    Vitale, S
    Arena, MG
    Biondi, E
    Gattuso, D
    Massidda, B
    Gasparini, G
    ANNALS OF ONCOLOGY, 2000, 11 : 42 - 42
12345